Effects of sodium citrate, low molecular weight heparin, and prostaglandin E1 on aggregation, fibrinogen binding, and enumeration of equine platelets

American Journal of Veterinary Research

Volumn 62, Issue 4, 2001, Pages 547-554

  Kingston, Janene K ^a   Bayly, Warwick M ^a   Sellon, Debra C ^a   Meyers, Kenneth M ^a   Wardrop, K Jane ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EQUIDAE;

ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; CALCIUM; CITRATE SODIUM; CITRIC ACID; FIBRINOGEN; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; PROSTAGLANDIN E1;

ANIMAL; BLOOD; CYTOLOGY; DRUG EFFECTS; FLOW CYTOMETRY; HEMATOCRIT; HORSE; METABOLISM; PHYSIOLOGY; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; VETERINARY;

ADENOSINE DIPHOSPHATE; ALPROSTADIL; ANIMALS; ANTICOAGULANTS; BLOOD PLATELETS; CALCIUM; CITRATES; FIBRINOGEN; FIBRINOLYTIC AGENTS; FLOW CYTOMETRY; HEMATOCRIT; HEPARIN, LOW-MOLECULAR-WEIGHT; HORSES; PLATELET AGGREGATION; PLATELET COUNT;

EID: 0000859241     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2001.62.547     Document Type: Article

References (43)

1. Weiss DJ, Evanson OA, McClenahan D, et al. Evaluation of platelet activation and platelet-neutrophil aggregates in ponies with alimentary laminitis. Am J Vet Res 1997;58:1376-1380.
2. Russell KE, Perkins PC, Hoffman MR, et al. Platelets from thrombocytopenic ponies acutely infected with equine infectious anemia virus are activated in vivo and hypofunctional. Virology 1999;259:7-19.
3. Weiss DJ. Evanson OA, Fagliari JJ, et al. Evaluation of platelet activation and platelet-neutrophil aggregates in Thoroughbreds undergoing near-maximal treadmill exercise. Am J Vet Res 1998;59:393-396.
4. Kingston JK, Sampson SN, Beard LA, et al. The effect of supramaximal exercise on equine platelet function. Equine Vet J Suppl 1999;30:181-183.
5. Bayly WM, Meyers KM, Keck MT, et al. Exercise-induced alterations in haemostasis in Thoroughbred horses. In: Snow DH, Persson SGD, Rose RJ, eds. Equine exercise physiology. Cambridge, England: Granta Editions, 1983;336-342.
6. Bayly WM, Meyers KM, Keck MT, et al. Effects of furosemide on exercise-induced alterations in haemostasis in Thoroughbred horses exhibiting post-exercise epistaxis. In: Snow DH, Persson SGD, Rose RJ, eds. Equine exercise physiology. Cambridge, England: Granta Editions, 1983;64-70.
7. Johnstone IB, Viel L, Crane S, et al. Hemostatic studies in racing Standardbred horses with exercise-induced pulmonary hemorrhage. Hemostatic parameters at rest and after moderate exercise. Can J Vet Res 1991;55:101-106.
8. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987;70:307-315.
9. Ruf A, Patscheke H. Flow cytometric detection of activated platelets: comparison of determining shape change, fibrinogen binding, and P-selectin expression. Semin Thromb Hemost 1995;21:146-151.
10. Michelson AD. Flow cytometry: a clinical test of platelet function. Blood 1996;87:4925-4936.
11. Weiss DJ, Evanson OA. Detection of activated platelets and platelet-leukocyte aggregates in horses Am J Vet Res 1997;58:823-827.
12. Brace LD, Fareed J. An objective assessment of the interaction of heparin and its fractions with human platelets. Semin Thromb Hemost 1985;11:190-198.
13. Barradas MA, Mikhailidis DP, Epemolu O, et al. Comparison of the platelet pro-aggregatory effect of conventional unfractionated heparins and a low molecular weight heparin fraction (CY 222). Br J Haematol 1987;67:451-457.
14. Serra A, Esteve J, Reverter JC, et al. Differential effect of a low-molecular-weight heparin (dalteparin) and unfractionated heparin on platelet interaction with the subendothelium under flow conditions. Thromb Res 1997;87:405-410.
15. 2+ accounts for the sex difference in the aggregation of human platelets in citrated platelet-rich plasma. Thromb Res 1990;58:47-60.
16. Brass LF, Shattil SJ, Kunicki TJ, et al. Effect of calcium on the stability of the platelet membrane glycoprotein IIb-IIIa complex. J Biol Chem 1985;260:7875-7881.
17. 2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997;96:1488-1494.
18. van Wyk V, Heyns AD. Low molecular weight heparin as an anticoagulant for in vitro platelet function studies. Thromb Res 1990;57:601-609.
19. Tomer A. A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia. Br J Haematol 1997;98:648-656.
20. 1 during preparation of platelet concentrates. Transfus Med 1996;6:249-254.
21. Dehmer GJ, Nichols TC, Bode AP, et al. Assessment of platelet activation by coronary sinus blood sampling during balloon angioplasty and directional coronary atherectomy. Am J Cardiol 1997; 80:871-877.
22. Janes SL, Wilson DJ, Chronos N, et al. Evaluation of whole blood flow cytometric detection of platelet bound fibrinogen on normal subjects and patients with activated platelets. Thromb Haemost 1993;70:659-666.
23. Welles EG, Bourne C, Tyler JW, et al. Detection of activated feline platelets in platelet-rich plasma by use of fluorescein-labeled antibodies and flow cytometry Vet Pathol 1994;31:553-560.
24. Levine PH. The effect of thrombocytopenia on the determination of platelet aggregation. Am J Clin Pathol 1976;65:79-82.
25. Brackett DJ, Schaefer CF, Gunn CG. Influence of time, temperature and platelet concentration on dog platelet aggregation. Thromb Res 1976;8:441-451.
26. Babcock RB, Dumper CW, Scharfman WB. Heparin-induced immune thrombocytopenia. N Engl J Med 1976;295:237-241.
27. Duncan SG, Meyers KM, Reed SM. Reduction of the red blood cell mass of horses: toxic effect of heparin anticoagulant therapy. Am J Vet Res 1983;44:2271-2276.
28. Kelton JG. Heparin-induced thrombocytopenia. Haemostasis 1986;16:173-186.
29. Monreal L, Villatoro AJ, Monreal M, et al. Comparison of the effects of low-molecular-weight and unfractioned heparin in horses. Am J Vet Res 1995;56:1281-1285.
30. Darien BJ. Heparin therapy: rationale and clinical indications. Campend Contin Educ Pract Vet 1993;15:1273-1276.
31. Wilde MI, Markham A. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs 1997;54:903-924.
32. Blockmans D, Bounameaux H, Vermylen J, et al. Heparin-induced thrombocytopenia platelet aggregation studies in the presence of heparin fractions or semi-synthetic analogues of various molecular weights and anticoagulant activities. Thromb Haemost 1986;55:90-93.
33. Goad KE, Home MK III, Gralnick HR. Pentosan-induced thrombocytopenia: support for an immune complex mechanism. Br J Haematol 1994;88:803-808.
34. Cahill MR, Macey MG, Newland AC. Fixation with formaldehyde induces expression of activation dependent platelet membrane glycoproteins, P selectin (CD62) and GP53 (CD63). Br J Haematol 1993;84:527-529.
35. Kohn CW, Brooks CL. Failure of pH to predict ionized calcium percentage in healthy horses. Am J Vet Res 1990;51:1206-1210.
36. Szenci O, Nemeth F, Stollar Z, et al. Effects of storage time and temperature on ionized calcium concentration in equine blood, plasma, and serum. J Am Vet Med Assoc 1994;204:1224-1226.
37. Judson GJ, Frauenfelder HC, Money GJ. Biochemical changes in thoroughbred racehorses following submaximal and maximal exercise. In: Snow DH, Persson SGD, Rose RJ, eds. Equine exercise physiology. Cambridge, England: Granta Editions, 1983; 408-415.
38. Lanza F, Beretz A, Stierle A, et al. Cyclic nucleotide phosphodiesterase inhibitors prevent aggregation of human platelets by raising cyclic AMP and reducing cytoplasmic free calcium mobilization. Thromb Res 1987;45:477-484.
39. Wong PY, McGiff JC, Sun FF, et al. 6-Keto-prostaglandin E, inhibits the aggregation of human platelets. Eur J Pharmacol 1979;60. 245-248.
40. 2 methyl ester. Prostaglandins Med 1980;4:453-463.
41. Harfenist EJ, Packham MA, Kinlough-Rathbone RL, et al. Inhibitors of ADP-induced platelet aggregation prevent fibrinogen binding to rabbit platelets and cause rapid deaggregation and dissociation of bound fibrinogen. J Lab Clin Med 1981;97:680-688.
42. Kinlough-Rathbone RL, Mustard JF, Perry DW, et al. Factors influencing the deaggregation of human and rabbit platelets. Thromb Haemost 1983;49:162-167.
43. Boudreaux MK, Wagner-Mann C, Purohit R, et al. Platelet function testing in the pony. Lab Anim Sci 1988;38:448-451.